Comparative Pharmacology
Head-to-head clinical analysis: SULFONAMIDES DUPLEX versus TRYSUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFONAMIDES DUPLEX versus TRYSUL.
SULFONAMIDES DUPLEX vs TRYSUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonamides are competitive antagonists of para-aminobenzoic acid (PABA) and inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
Trypanocidal agent; forms a complex with DNA and inhibits nucleic acid synthesis.
Oral: 500-1000 mg twice daily; maximum 2000 mg/day.
2 tablets (each containing sulfamethoxazole 400 mg and trimethoprim 80 mg) orally every 12 hours for 10-14 days.
None Documented
None Documented
Terminal half-life: 7-12 hours in patients with normal renal function; prolonged to 24-50 hours in renal impairment (CrCl <30 mL/min) due to reduced elimination.
Terminal elimination half-life: 8-10 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70-100% unchanged drug via glomerular filtration and tubular secretion; fecal/biliary: <5%.
Renal: approximately 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: 15-20% as metabolites; small amount in feces.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic